A Facile Stereoselective Domino Approach for the Construction of Novel Bis(spiropiperidone)–Tetrahydrothiophene Hybrid Heterocycles

Chelliah Bharkavi; Sundaravel Vivek Kumar; Subbu Perumal

doi:10.1055/s-0034-1380722

Synlett, Inhaltsverzeichnis

Synlett 2015; 26(12): 1665-1670
DOI: 10.1055/s-0034-1380722

letter

A Facile Stereoselective Domino Approach for the Construction of Novel Bis(spiropiperidone)–Tetrahydrothiophene Hybrid Heterocycles

Chelliah Bharkavi

,

Sundaravel Vivek Kumar

,

Subbu Perumal*

Abstract

Alle Artikel dieser Rubrik

Abstract

A library of novel bis-spiropiperidone–tetrahydrothiophene hybrid heterocycles have been synthesized via pseudo-three-component domino reaction of (3E,5E)-3,5-bis(arylidene)-1-methyl/benzyl piperidin-4-ones and 1,4-dithiane-2,5-diol in the presence of triethylamine. This transformation presumably proceeds via two annulations each involving the generation of 2-mercaptoacetaldehyde from 1,4-dithiane-2,5-diol–Michael addition–intramolecular aldol sequence which result in the creation of four new bonds in a one-pot operation. The advantages of this protocol are high atom economy, high stereoselectivity, short reaction time, and operational simplicity.

Key words

domino reactions - stereoselectivity - (3E,5E)-3,5-bis(arylidene)-1-methyl/benzylpiperidin-4-ones - 1,4-dithiane-2,5-diol - bis(spiropiperidone)–tetrahydrothiophene hybrids

Volltext

Referenzen

References and Notes
1 Both authors contributed equally to this work.

2a Tietze LF. Chem. Rev. 1996; 96: 115
2b Tietze LF, Brasche G, Gericke K. Domino Reactions in Organic Synthesis . Wiley-VCH; Weinheim: 2006
2c Guo H.-C, Ma J.-A. Angew. Chem. Int. Ed. 2006; 45: 354 ; Angew. Chem. 2006, 118, 362
2d Wasilke J.-C, Obrey SJ, Baker RT, Bazan GC. Chem. Rev. 2005; 105: 1001
2e Nicolaou KC, Edmonds DJ, Bulger PG. Angew. Chem. Int. Ed. 2006; 45: 7134 ; Angew. Chem. 2006, 118, 7292
2f Chapman CJ, Frost CG. Synthesis 2007; 1
2g Pellissier H. Tetrahedron 2006; 62: 1619
2h Pellissier H. Tetrahedron 2006; 62: 2143
2i Filloux CM, Lathrop SP, Rovis T. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 20666

3a Srivastava N, Mittal A, Kumar A. J. Chem. Soc., Chem. Commun. 1992; 493
3b James DM, Kunze HB, Faulkner DJ. J. Nat. Prod. 1991; 54: 1137
3c Kobayashi J, Tsuda M, Agemi K, Shigemiri H, Ishibashi M, Sasaki T, Mikami Y. Tetrahedron 1991; 47: 6617

4 Benetti S, De Risi C, Pollini GP, Zanirato V. Chem. Rev. 2012; 112: 2129

5a Ward TR. Chem. Eur. J. 2005; 11: 3798
5b FernandezMejía C. J. Nutr. Biochem. 2005; 16: 424
5c Zempleni J. Annu. Rev. Nutr. 2005; 25: 175
5d Gallienne E, Benazza M, Demailly G, Bolte J, Lemaire M. Tetrahedron 2005; 61: 4557
5e Begley TP. Nat. Prod. Rep. 2006; 23: 15

6a Mohan S, Jayakanthan K, Nasi R, Kuntz DA, Rose DR, Pinto BM. Org. Lett. 2010; 12: 1088
6b Yoshikawa M, Murakmi T, Yashiro K, Matsuda H. Chem. Pharm. Bull. 1998; 46: 1339

7 Yoshikawa M, Murakami T, Shimada H, Matsuda H, Yamahara J, Tanabe G, Muraoka O. Tetrahedron Lett. 1997; 38: 8367
8 Tanabe G, Sakano M, Minematsu T, Matusda H, Yoshikawa M, Muraoka O. Tetrahedron 2008; 64: 10080
9 Yoshikawa M, Xu FM, Nakamura S, Wang T, Matsuda H, Tanabe G, Muraoka O. Heterocycles 2008; 75: 1397
10 Tanabe G, Xie W, Ogawa A, Cao C, Minematsu T, Yoshikawa M, Muraoka O. Bioorg. Med. Chem. Lett. 2009; 19: 2195
11 Tanabe G, Yoshikai K, Hatanaka T, Yamamoto M, Shao Y, Minematsu T, Muraoka O, Wang T, Matsuda H, Yoshikawa M. Bioorg. Med. Chem. 2007; 15: 3926
12 Nasi R, Patrick BO, Sim L, Rose DR, Pinto BM. J. Org. Chem. 2008; 73: 6172

13a Kuwahara T, Kudoh T, Nagase H, Takamiya M, Nakano A, Ohtsuka T, Yoshizaki H, Arisawa M. Eur. J. Pharmacol. 1992; 221: 99
13b Ohtsuka T, Kudoh T, Shimma N, Kotaki H, Nakayama N, Itezono Y, Fujisaki N, Watanabe J, Yokose K, Seto H. J. Antibiot. 1992; 45: 140
13c Watanabe J, Fujisaki N, Fujimori K, Anzai Y, Oshima S, Sano T, Ohtsuka T, Watanabe K, Okuda T. J. Antibiot. 1993; 46: 1
13d Ohtsuka T, Kotaki H, Nakayama N, Itezono Y, Shimma N, Kudoh T, Kuwahara T, Arisawa M, Yokose K. J. Antibiot. 1993; 46: 11
13e Ohtsuka T, Nakayama N, Itezono Y, Shimma N, Kuwahara T, Yokose K, Seto H. J. Antibiot. 1993; 46: 18
13f Kuwahara T, Kudoh T, Nakano A, Yoshizaki H, Takamiya M, Nagase H, Arisawa M. Neurosci. Lett. 1993; 158: 1
13g Murayama T, Matsumori Y, Iwata N, Ito M, Taniguchi T, Chihara K, Matsui T. Jpn. J. Cancer Res. 1996; 87: 743

14 Volkmann RA, Kelbaugh PR, Nason DM, Jasys VJ. J. Org. Chem. 1992; 57: 4352
15 Haraguchi K, Shimada H, Tanaka H, Hamasaki T, Baba M, Gullen EA, Dutschman GE, Cheng YC. J. Med. Chem. 2008; 51: 1885
16 Kato T, Tsuzuki K. JP 147881, 1992 ; Chem. Abstr. 1992, 120, 106750
17 Jeong LS, Lee HW, Jacobson KA, Kim HK, Shin DH, Lee JA, Gao Z.-G, Lu C, Duong HT, Gunaga P, Lee SK, Jin DZ, Chun MW, Moon HR. J. Med. Chem. 2006; 49: 273
18 Chorghade MS, Gurjar MK, Palakodety RK, Lalitha SV. S, Sadalapure K, Adhikari SS, Murugaiah AM. S, Rao BV, Talukdar A, Islam A, Hariprasad C, Rao AV. R. WO US 2000001670 A1, 2000 ; Chem. Abstr. 1999, 132, 93203.
19 Tsygoanko VA, Blume YB. Biopolim. Kletka 1997; 13: 484
20 Zempleni J, Wijeratne SS, Hassan YI. Biofactors 2009; 35: 36
21 Williams DR, Jass PA, Tse HL. A, Gaston RD. J. Am. Chem. Soc. 1990; 112: 4552

22a Zanardi J, Lamazure D, Miniere S, Reboul V, Metzner P. J. Org. Chem. 2002; 67: 9083
22b Zanardi J, Leriverend C, Aubert D, Julienne K, Metzner P. J. Org. Chem. 2001; 66: 5620
22c Julienne K, Metzner P. J. Org. Chem. 1998; 63: 4532

23a Mukaiyama T, Asanuma H, Hachiya I, Harada T, Kobayashi S. Chem. Lett. 1991; 7: 1209
23b Hauptman E, Shapiro R, Marshall W. Organometallics 1998; 17: 4976

24a Ileana B, Dobre V, Niculescu-Duvaz I. J. Prakt. Chem. 1985; 327: 667
24b Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung C, Chen X, Walters KJ, Roden RB. S. Cancer Cell 2013; 24: 791

25 Reddy PA, Woodward KE, Mcllheran SM, Hsiang BC. H, Latifi TN, Hill MW, Rothman SM, Ferrendelli JA, Covey DF. J. Med. Chem. 1997; 40: 44
26 Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TW. W. Int. Immunopharmacol. 2012; 12: 368
27 Srinivasan M, Perumal S, Selvaraj S. Chem. Pharm. Bull. 2006; 54: 795
28 Pati HN, Das U, Das S, Bandy B, Clercq ED, Balzarini J, Kawase M, Sakagami H, Quail JW, Stables JP, Dimmock JR. Eur. J. Med. Chem. 2009; 44: 54

29a Suresh Kumar R, Perumal S, Arun Shetty K, Yogeeswari P, Sriram D. Eur. J. Med. Chem. 2010; 45: 124
29b Ranjith Kumar R, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D. J. Med. Chem. 2008; 51: 5731

30 Sivakumar S, Ranjith Kumar R, Ashraf Ali M, Choon TS. Eur. J. Med. Chem. 2013; 65: 240
31 Duan SW, Li Y, Liu YY, Zou YQ, Shi DQ, Xiao WJ. Chem. Commun. 2012; 48: 5160

32a Szwed KB, Grochowski J, Obara A, Rys B, Serda P. J. Org. Chem. 2001; 66: 7205
32b Szwed KB, Gil R. Monatsh. Chem. 2004; 135: 1415
32c Szwed KB, Budzowski A, Gil R, Serda P. Monatsh. Chem. 2010; 141: 63

33a Giera H, Huisgen R, Langhals E, Polborn K. Helv. Chim. Acta 2002; 85: 1523
33b Huisgen R, Giera H, Polborn K. Tetrahedron 2005; 61: 6143

34a D’yakonov VA, Trapeznikova OA, Ibragimov AG, Dzhemilev UM. Russ. Chem. Bull. Int. Ed. 2009; 58: 948
34b D'yakonov VA, Ibragimov AG, Khalilov LM, Makarov AA, Timerkhanov RK, Tuktarova RA, Trapeznikova OA, Galimova LF. Chem. Heterocycl. Compd. 2009; 45: 317

35 Vivek Kumar S, Prasanna P, Perumal S. Tetrahedron Lett. 2013; 54: 6651

For selected recent examples, see:

36a Muthusaravanan S, Sasikumar C, Devi Bala B, Perumal S. Green Chem. 2014; 16: 1297
36b Gunasekaran P, Indumathi S, Perumal S. RSC Adv. 2013; 3: 8318
36c Muthusaravanan S, Devi Bala B, Perumal S. Tetrahedron Lett. 2013; 54: 5302
36d Prasanna P, Perumal S, Menéndez JC. Green Chem. 2013; 15: 1292
36e Prasanna P, Vivek Kumar S, Gunasekaran P, Perumal S. Tetrahedron Lett. 2013; 54: 3740
36f Gunasekaran P, Balamurugan K, Sivakumar S, Perumal S, Menéndez JC, Almansour AI. Green Chem. 2012; 14: 750
36g Indumathi S, Perumal S, Menéndez JC. J. Org. Chem. 2010; 75: 472

37 General Procedure for the Synthesis of 1,8-Bis(aryl)-4,11-dihydroxy-13-methyl/benzyl-2,9-dithia-13-azadispiro[4.1.4⁷.3⁵]tetradecan-6-ones 3a–p A mixture of (3E,5E)-3,5-bis(arylidene)-1-methyl/benzylpiperidin-4-one (1 mmol), 1,4-dithiane-2,5-diol (1 mmol), and Et₃N (0.25 equiv) in CH₂Cl₂ (6 mL) was heated under reflux for 3–4 h. After completion of the reaction (TLC), the solvent was removed and the product was purified by flash column chromatography using a PE–EtOAc mixture (4:1 v/v) as eluent to afford pure compound
38 Characterization Data of Representative Compounds 1,8-Bis(4-fluorophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.4⁷.3⁵]tetradecan-6-one (3a) White solid; yield 88% (0.38 g); mp 215–216 °C. ¹H NMR (300 MHz, CDCl₃ + DMSO-d ₆): δ = 1.64 (d, 2 H, J = 12.3 Hz), 2.22 (s, 3 H, NCH₃), 2.64 (d, 2 H, J = 12.3 Hz), 2.97 (d, 2 H, J = 12.3 Hz), 3.48 (dd, 2 H, J = 12.3, 4.8 Hz), 5.03 (d, 2 H, J = 4.5Hz,), 5.28 (t, 2 H, J = 4.4 Hz), 5.72 (s, 2 H), 6.81–6.87 (m, 4 H, ArH), 7.34–7.44 (m, 4 H, ArH). ¹³C NMR (75 MHz, CDCl₃ + DMSO-d ₆): δ = 36.6, 46.5, 50.7, 57.6, 68.2, 79.4, 114.0 (² J _C,_F = 20.9 Hz), 131.2 (³ J _C,_F = 7.8 Hz), 131.4, 161.5 (¹ J _C,_F = 244.9 Hz), 203.5. Anal. Calcd for C₂₄H₂₅F₂NO₃S₂: C, 60.36; H, 5.28; N, 2.93. Found: C, 60.29; H, 5.24; N, 2.99. ESI-MS: m/z calcd: 477.12; found: 478.07 [M⁺]. 1,8-Bis(4-chlorophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.4⁷.3⁵]tetradecan-6-one (3b) White solid; yield 85% (0.36 g); mp 225–226 °C. ¹H NMR (300 MHz, CDCl₃ + DMSO-d ₆): δ = 1.62 (d, 2 H, J = 12.0 Hz), 2.22 (s, 3 H, NCH₃), 2.64 (d, 2 H, J = 12.0 Hz), 2.95 (d, 2 H, J =12.3 Hz), 3.49 (dd, 2 H, J = 12.2, 4.4 Hz), 5.10 (d, 2 H, J = 3.9 Hz), 5.27 (t, 2 H, J = 5.9 Hz), 5.67 (s, 2 H), 7.13 (d, 4 H, J = 8.4 Hz, ArH), 7.33 (d, 4 H, J = 8.4 Hz, ArH). ¹³C NMR (75 MHz, CDCl₃ + DMSO-d ₆): δ = 36.0, 45.8, 50.1, 56.7, 67.6, 78.6, 126.7, 130.4, 131.8, 133.8, 202.8. Anal. Calcd for C₂₄H₂₅Cl₂NO₃S₂: C, 56.47; H, 4.94; N, 2.74. Found: C, 56.58; H, 4.88; N, 2.69. ESI-MS: m/z calcd: 509.07; found: 546.16 [M + Cl]. 1,8-Bis(4-bromophenyl)-4,11-dihydroxy-13-methyl-2,9-dithia-13-azadispiro[4.1.4⁷.3⁵]tetradecan-6-one (3c) White solid; yield 83% (0.33 g); mp 227–228 °C. ¹H NMR (300 MHz, CDCl₃ + DMSO-d ₆): δ = 1.64 (d, 2 H, J = 12.0 Hz), 2.22 (s, 3 H, NCH₃), 2.63 (d, 2 H, J = 12.0 Hz,), 2.99 (d, 2 H, J = 12.3 Hz), 3.48 (dd, 2 H, J = 12.3, 4.8 Hz), 4.99 (d, 2 H, J = 4.5 Hz), 5.26 (t, 2 H, J = 4.4 Hz), 5.69 (s, 2 H), 7.24–7.30 (m, 6 H, ArH), 7.42–7.43(m, 2 H, ArH). ¹³C NMR (75 MHz, CDCl₃ + DMSO-d ₆): δ = 36.5, 46.2, 50.7, 57.2, 68.0, 79.2, 120.7, 130.2, 131.2, 134.7, 203.3. Anal. Calcd for C₂₄H₂₅Br₂NO₃S₂: C, 48.09; H, 4.20; N, 2.34. Found: C, 48.12; H, 4.28; N, 2.30. ESI-MS: m/z calcd: 598.96; found: 634.16 [M + Cl]
39 General Procedure for the Synthesis of 3-[(E)-4-arylidene]-1-methyl-5-[(E)-4-arylidene]piperidin-4-ones 1q,r The synthesis of (E)-1-methyl-3-(arylidene)piperidin-4-ones was performed from our earlier reported procedure.⁴² Unsymmetrically substituted 3-[(E)-4-arylidene]-1-methyl-5-[(E)-4-arylidene]piperidin-4-one were synthesized from previous reports⁴³ with simple modification. A mixture of (E)-1-methyl-3-(arylidene)piperidin-4-ones (1 mmol) and Ba(OH)₂·8H₂O (1 mmol) in EtOH was reacted under stirring conditions for 5 min. Then aromatic aldehyde (1 mmol) was dissolved in EtOH and was added dropwise. After completion of the addition the resulting mixture was stirred for further 3 h. After completion of the reaction with evident TLC, the precipitated solid was filtered and washed with cold EtOH that afforded pure 1q and 1r.
40 Characterization Data of Unsymmetrically Substituted Diarylidines 3-[(E)-benzylidene]-1-methyl-5-[(E)-4-methylbenzylidene]piperidin-4-one (1q) Yellow solid; yield 88% (0.39 g); mp 185–186 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.40 (s, 3 H, NCH₃), 2.48 (s, 3 H), 3.79 (s, 4 H), 7.22–7.32 (m, 7 H, ArH), 7.41–7.43 (m, 2 H, ArH), 7.81(s, 2 H, ArH). ¹³C NMR (75 MHz, CDCl₃): δ = 21.4, 45.8, 57.1, 129.3, 130.5, 132.4, 132.5, 136.4, 139.3, 186.9. Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.05; H, 6.86; N, 4.69. 1-Methyl-3-[(E)-4-methylbenzylidene]-5-[(E)-4-nitrobenzylidene]piperidin-4-one (1r) Yellow solid; yield 90% (0.46 g); mp 164–165 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.40 (s, 3 H, NCH₃), 2.48 (s, 3 H), 3.73 (s, 2 H), 3.79 (s, 2 H), 7.25, (d, 2 H, J = 8.4 Hz, ArH), 7.32 (d, 2 H, J = 8.1 Hz, ArH), 7.53 (d, 2 H, J = 8.7 Hz, ArH), 7.79 (s, 1 H), 7.81 (s, 1 H), 8.28 (d, 2 H, J = 8.7 Hz, ArH). ¹³C NMR (75 MHz, CDCl₃): δ = 21.3, 45.7, 56.6, 57.0, 123.5, 129.3, 130.5, 130.6, 131.7, 131.9, 132.7, 136.2, 137.2, 139.7, 141.6, 147.2, 186.1. Anal. Calcd for C₂₁H₂₀N₂O₃: C, 72.40; H, 5.79; N, 8.04. Found: C, 72.46; H, 5.71; N, 8.16. ESI-MS: m/z calcd: 348.15; found: 349.18 [M⁺]
41 Crystallographic data (excluding structure factors) for compound 3b in this letter have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 999878. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].
42 Suresh Kumar R, Perumal S, Kagan HB, Guillot R. Tetrahedron Asymmetry 2007; 18: 170
43 Mai A, Cheng D, Bedford MT, Valente S, Nebbioso A, Perrone A, Brosch G, Sbardella G, De Bellis F, Miceli M, Altucci L. J. Med. Chem. 2008; 51: 2279